Find answers in your patient's blood

Targeted liquid biopsy for all advanced solid tumors to support your clinical decisions

74 genes

CNVs, SNVs, Indels

TERT promoter

Unusual splicing

Gene translocations

OncoSELECT™
by OncoDNA

WHY **CHOOSE** ONCOSELECT®?

OncoSELECT® helps optimize treatment strategies across all advanced solid tumors from just two tubes of blood, and matches patients with **targeted therapy**, **hormone therapy** and **potential clinical trials** to improve your patients' clinical outcomes. Rely on a blood-based biomarker-informed approach to make quick and personalized treatment plans for your patient.

IN WHAT **SCENARIOS** IS ONCOSELECT® USEFUL?

When your patients cannot have their tumor biopsied, when their tumor tissue sample is too old or too scarce for comprehensive biomarker testing, OncoSELECT® is the perfect alternative to support your clinical decisions thanks to a **fast** and **minimally invasive** analysis of circulating tumor DNA from a blood sample.

OncoSELECT® is available for **all advanced solid tumors in adults** and recommended for **stage 3 or 4** cancer patients when:

- Patient is receiving chemotherapy in neoadjuvant setting. OncoSELECT® may be used to inform on the **patient's response to treatment**.
- Patient is relapsing under current therapy. OncoSELECT® may be used after a line of treatment to **identify if the patient developed resistant mutations**.
- Patient is wild type for specific genes related to their cancer type based on the analysis of their solid biopsy. OncoSELECT® may be performed before the first line of treatment to **assess the heterogeneity of the disease**.

Whole exons

ARID1A	CHEK2	NF1
ATM	FANCA	PALB2
ATR	FANCL	PTEN
BARD1	FGFR1	RAD51C
BRCA1	FGFR2	RAD51D
BRCA2	FGFR3	RAD54L
BRIP1	KEAP1	STK11
CDK12	MLH1	
CDKN2A	MRE11A	
CHEK1	NBN	

Hotspots

AKT1	FOXL2	MAP2K1
ALK	GNA11	MYOD1
AR	GNAQ	NTRK1
ARAF	GNAS	NTRK2
BRAF	H3F3A	NTRK3
CTNNB1	H3F3B	PDGFRA
DICER1	H3C2	POLE
EGFR	IDH1	ROS1
ERBB4	IDH2	TERT
ESR1	KIT	

Genes associated with translocatons

ALK	FGFR2	NTRK2
BRAF	FGFR3	NTRK3
CD74	KIF5B	RET
EGFR	KIT	ROS1
EML4	MET	SDC4
ETV6	NPM1	SLC34A2
EZR	NRG1	
FGFR1	NTRK1	

Unusual splicing genes

BRCA1	BRCA2	MET

OPTIMIZED PROCESS TO ACHIEVE **GREATER SENSIBILITY AND SPECIFICITY**

VAF= 0,25%
98,5 > % sensitivity
99,9 > % specificity
99,9 > % accuracy

ONCOSELECT® **STEP BY STEP**

Our teams are at hand to assist you every step of the way – from discussing the relevance of the test for your patient and easing the sample collection to understanding the clinical recommendations listed in the report.



A **63-year-old man** with **stage IV prostate cancer** (mCRPC), **metastasized** to lung, lymph node, bone

OncoSELECT allowed the identification of an **AR V890M** variant which explained the lack of clinical benefit of the previous hormonal therapies. Moreover, the detection of **BRCA2 somatic** and **ATM R3008C** variants led to the prescription of **olaparib** with a complete response, and no relapse was identified for the last 6 months.

A **55-year-old non-smoker male** was diagnosed with metastatic non-small-cell lung carcinoma (**NSCLC**)

Oncologist requested to perform a liquid biopsy test since the lung needle biopsy obtained was of limited quantity. The patient was progressing under erlotinib and OncoSELECT allowed the detection of **EGFR T790M** variant. The detection of this variant led the oncologist to choose **osimertinib** which resulted in good response without any known relapse so far.

A **43-year-old woman** with s**tage IV breast HR cancer**, with recent relapse

OncoSELECT was performed because no solid biopsy was available for this patient. It allowed the identification of **ESR1 L536Q** and **PIK3CA E545K** mutations. Based on these biomarkers, it was decided to prescribe **alpelisib** in combination with **fulvestrant**, an FDA-approved treatment, to the patient. The patient responded well to the treatment without any relapse in the last 6 months.

ONCOSELECT® **REPORT**

The OncoSELECT report helps you f**lag potential resistance mechanisms** and **optimize treatment strategies**.

Each report:

- Contains the patient's medical information (patient diagnosis, tumor type and stage, blood draw date …)
- Reveals all actionable variants and their biological and therapeutical classifications according to ACMG/AMP guidelines
- Reveals a patient's receptiveness to targeted therapy or hormonal therapy
- Details all relevant recruiting clinical trials with detailed information on the drug development stage and its clinical benefit for your patient.



Contact us to discuss your patient case

OncoDNA-BioSequence

customersupport@oncodna.com +32 (0)71 18 35 00

Ref: MKT_BR_ONCOSELECT_200125